-0.92%
Today
Loading 1D prices…
Company profile
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
Sector
Health Care
Industry
Electromedical & Electrotherapeutic Apparatus
Exchange
Nasdaq
Display currency
USD
Location
Gloucester, United States
Employees
3.3K
Fiscal year end
1231
CIK
1639691
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ITGRInteger Holdings Corporation Common Stock | $4.3B | $1.9B | +5.55% | $2.89 | +0.17% | Hold |
| TMDXTransMedics Group Inc. Common Stock | $3B | $605.5M | +31.43% | $4.87 | -1.03% | Buy |
| AXGNAxogen Inc. Common Stock | $2.7B | $225.2M | -6.97% | -$0.34 | -0.33% | Buy |
| BLFSBioLife Solutions Inc. Common Stock | $1.8B | $96.2M | -4.78% | -$0.10 | +2.10% | Hold |
| CNMDCONMED Corporation Common Stock | $1.4B | $1.4B | +3.43% | $1.51 | -1.93% | Sell |